Gregory Weaver Net Worth

The estimated Net Worth of Gregory L Weaver is at least $72.1 Thousand dollars as of 15 November 2023. Mr. Weaver owns over 50,000 units of Atossa Therapeutics Inc stock worth over $84 and over the last 16 years he sold ATOS stock worth over $72,008. In addition, he makes $0 as Independent Director at Atossa Therapeutics Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Weaver ATOS stock SEC Form 4 insiders trading

Gregory has made over 13 trades of the Atossa Therapeutics Inc stock since 2010, according to the Form 4 filled with the SEC. Most recently he sold 50,000 units of ATOS stock worth $32,500 on 15 November 2023.

The largest trade he's ever made was exercising 164,581 units of Atossa Therapeutics Inc stock on 2 July 2021 worth over $365,370. On average, Gregory trades about 9,292 units every 123 days since 2009. As of 15 November 2023 he still owns at least 55 units of Atossa Therapeutics Inc stock.

You can see the complete history of Mr. Weaver stock trades at the bottom of the page.

Gregory Weaver biography

Gregory L. Weaver serves as Independent Director of the Company. Mr. Weaver served as Chief Financial Officer of Eloxx Pharmaceuticals, Inc. (Nasdaq: ELOX) a publicly traded biotech company from September 2017 to March 2020. Mr. Weaver previously served as the Chief Financial Officer from October 2015 to August 2017 with ProMetic Life Sciences, and from January to October 2015 with Oryzon Genomics. Mr. Weaver received his undergraduate degree in finance from Trinity University and his MBA from Boston College. Mr. Weaver has been selected to serve on the Company’s Board of Directors because of his qualifications as a business executive and audit committee financial expert, and his current and prior experience as a Chief Financial Officer, director and committee member of public companies. From 2014 to January 2020, Mr. Weaver served on the board of directors of Egalet Corp., a publicly traded biotech company, and from September 2014 to January 2015 on the board of directors of Oryzon Genomics, a publicly traded biotech company.

How old is Gregory Weaver?

Gregory Weaver is 63, he's been the Independent Director of Atossa Therapeutics Inc since 2013. There are 4 older and 3 younger executives at Atossa Therapeutics Inc. The oldest executive at Atossa Therapeutics Inc is Stephen Galli, 73, who is the Independent Director.

What's Gregory Weaver's mailing address?

Gregory's mailing address filed with the SEC is C/O ATOSSA THERAPEUTICS, INC.,, 107 SPRING STREET, SEATTLE, WA, 98104.

Insiders trading at Atossa Therapeutics Inc

Over the last 12 years, insiders at Atossa Therapeutics Inc have traded over $114,740 worth of Atossa Therapeutics Inc stock and bought 274,300 units worth $204,285 . The most active insiders traders include Gregory L Weaver, Steven C Quay, and Shu Chih Chen. On average, Atossa Therapeutics Inc executives and independent directors trade stock every 205 days with the average trade being worth of $38,260. The most recent stock trade was executed by Jonathan Finn on 10 April 2024, trading 25,000 units of ATOS stock currently worth $44,250.

What does Atossa Therapeutics Inc do?

atossa therapeutics, inc. develops and markets medical devices, laboratory tests, and therapeutics to address breast health conditions in the united states. the company's lead program is the development of endoxifen, an active metabolite of tamoxifen which is in phase ii studies to treat and prevent breast cancer. it is also developing intraductal microcatheter technology to target the delivery of therapies, including fulvestrant, immunotherapies, and chimeric antigen receptor t-cell therapies, directly to the site of breast cancer. the company was formerly known as atossa genetics inc. and changed its name to atossa therapeutics, inc. in january 2020. atossa therapeutics, inc. was founded in 2009 and is headquartered in seattle, washington.

Complete history of Mr. Weaver stock trades at Atossa Therapeutics Inc, Imunon Inc, and Eloxx Pharmaceuticals Inc

Atossa Therapeutics Inc executives and stock owners

Atossa Therapeutics Inc executives and other stock owners filed with the SEC include:

• Steven Quay,
  Chairman of the Board, President, Chief Executive Officer
• Kyle Guse,
  Chief Financial Officer, General Counsel, Secretary
• Dr. Steven C. Quay,
  Chairman, CEO & Pres
• Kyle Guse CPA, Esq., CPA,
  CFO, Gen. Counsel & Sec.
• Shu-Chih Chen,
  Director
• Gregory Weaver,
  Independent Director
• Scott Gordon,
  IR Contact Officer
• Richard Steinhart,
  Independent Director
• H. Lawrence Remmel,
  Independent Director
• Stephen Galli,
  Independent Director
• Janet Rose Rea MSPH, RAC,
  Sr. VP of Regulatory, Quality & Clinical Affairs
• Delly Behen P.H.R.,
  VP of Admin. & HR
• Heather Rees,
  VP of Fin. & Accounting
• Janet Rose Rea,
  Sr. VP of Regulatory, Quality & Clinical Affairs
• Scott Youmans,
  Chief Operating Officer
• Heather Rees,
  SVP, Finance and Accounting
• Jonathan Finn,
  
• Tessa Cigler,
  
• Christopher S. Destro,
  Sr. VP, Sales and Marketing
• John Barnhart,
  Director
• John E Sawyer,
  See Remarks
• Peter J. Carbonaro,
  Sr. Vice President, Operations
• Ben R Chen,
  Sr. VP of Glob. Reg. Affairs
• Alexander D Cross,
  Director